

5 **FERTILITY IMPAIRING VACCINE CONTAINING AVIAN ZONA**
 PELLUCIDA PROTEIN AND METHOD OF USE

 This application claims the benefit of U.S. Provisional Applications
Serial No. 60/141,929, filed July 1, 1999, and 60/162,984, filed November 2,
10 1999.

Background of the Invention

 Population control of both domesticated and wild, free-roaming
animals has been a major problem around the world. Overpopulation in dogs and
15 cats results in millions of euthanasias of unwanted pets yearly in the United
States alone, and overpopulation of wild animals causes destruction of habitat
and threatens other species within the ecosystem. In humane shelters population
control of unwanted pets is currently achieved through euthanasia of the
animals. In general, after capture, dogs are held for a period of one week. If
20 they are not adopted, they are humanely destroyed.

 Finding a socially acceptable as well as a safe and effective means
of controlling excess populations of animals has been extremely difficult.
Traditional methods of population control in dogs have been largely
unsuccessful. Surgical spaying is a laborious procedure, requiring the initial
25 induction of the animal, gas anesthesia during surgery, a surgical pack with
suture materials and post-operative medications. Common surgical
complications include problems associated with the procedure itself, allergic
reactions to anesthetics or post-operative medications, and adverse local or
systemic effects during the recovery period. Examples include ovarian remnant
30 syndrome, where dogs continue to cycle despite being spayed, uterine infections,
abdominal hemorrhage, and premature opening of the suture line. A substantial
recovery period is typically needed even after an uncomplicated procedure.

Surgical spaying is also expensive, and pet owners are often unwilling to assume the costs.

The use of a reversible contraceptive is an attractive alternative to surgical spaying. However, conventional hormonal therapies that have been used to curb pet overpopulation are inconvenient because they usually require daily administration of the drug. Furthermore, most protracted hormonal therapies have undesirable side effects such as uterine infections, mammary cancer, and diabetes.

A vaccine comprising porcine zona pellucida protein (pZP) and an adjuvant comprising synthetic trehalose dicorynomycolate has been successfully used to cause immunocontraception in horses (P. Willis et al., J. Equine Vet. Sci. 14:364-370 (1994)) and elephants (R. Fayrer-Hosken, Wildlife Soc. Bull., 25(1):18-21 (1997)). Injection of total heat solubilized pZP into horses results in an immunocontraceptive effect that lasts for about 12 months and has been effective in reducing fertility of free-roaming horses (Kirkpatrick et al., J. Reprod. Fert. 94:437-444 (1992)). The pZP vaccine has been used for more than 8 years in horses with no adverse reactions; nor does the vaccine affect the feti of pregnant mares.

A pZP vaccine has been administered to dogs as well, albeit with somewhat less success. Mahi-Brown et al. have shown that infertility in the female dog can be achieved by vaccinating with a crude pZP preparation, but vaccination was accompanied by abnormal estrus cycles and other deleterious side effects, such as ovarian cyst formation (J. Exp. Zool., 222:89-95 (1982); Am. J. Reprod. Immunol. Microbiol., 18: 94-103 (1988)).

Porcine zona pellucida protein is obtained from pig ovaries, thus the amount of vaccine that can be prepared is limited by the supply of pig ovaries. Dunbar et al. (e.g., EP 599822, U.S. Pat. No. 5,637,300) have experimented with reproductive control in non-rodent mammals using a recombinant zona pellucida protein. However, due to limitations imposed by recombinant DNA technology and available expression systems, the recombinant protein lacks the glycosylation pattern of the native glycoprotein and its immunogenicity has not been satisfactorily demonstrated. What is clearly needed to combat overpopulation of domesticated and wild, free-roaming

animals is a low cost contraceptive or sterilant that possesses a high degree of efficiency, lacks of harmful side effects, is amenable to remote delivery, requires a minimal number of administrations, and is easy to produce.

5

Summary of the Invention

10 The present invention provides a fertility impairing vaccine and a method for impairing fertility in an animal. One embodiment of the fertility impairing vaccine, referred to herein as a protein vaccine, comprises a polypeptide comprising at least one avian zona pellucida protein or an immunogenic fragment thereof. These proteins are related to the mammalian zona pellucida proteins. Optionally, the protein vaccine of the invention further includes a polypeptide comprising a porcine zona pellucida protein or an immunogenic fragment thereof.

15 Another embodiment of the fertility impairing vaccine, referred to herein as a polynucleotide vaccine, comprises a polynucleotide comprising at least one nucleotide sequence that encodes a polypeptide comprising an avian zona pellucida protein or an immunogenic fragment thereof. Optionally, the polynucleotide vaccine of the invention further includes a polynucleotide comprising a nucleotide sequence that encodes a polypeptide comprising a porcine zona pellucida protein or an immunogenic fragment thereof.

20 The fertility impairing vaccine of the invention optionally further includes an immunological adjuvant or immunostimulant, preferably synthetic trehalose dicorynomycolate (STDCM). Also optionally, the fertility impairing vaccine contains an oil, preferably squalene oil.

25 The method for impairing fertility in the animal comprises administering to the animal the fertility impairing vaccine of the invention in a manner and an amount effective to cause fertility impairment in the animal. When administered as an immunocontraceptive, the fertility impairing vaccine causes temporary, reversible infertility in the animal. When administered as an immunosterilant, the fertility impairing vaccine causes permanent, irreversible infertility in the animal. In dogs and cats, for example, immunosterilization is

30

far preferable to surgical sterilization and hormone regimens as a population control tool.

The fertility impairing vaccine of the invention can generally be used for immunological control of fertility and reproduction in any desired animal population, whether domestic or wild. As an example, the fertility impairing vaccine can be used to control ferret dog and cat populations by development of a species-specific oral delivery vehicle. As another example, the fertility impairing vaccine can be used to control wild horse, deer or elephant populations when formulated as a single dose dart or bullet that can be administered without capture or confinement of the animal.

Detailed Description of the Preferred Embodiments

The fertility impairing vaccine of the invention contains a polypeptide comprising at least one avian zona pellucida protein (aZP) or an immunogenic fragment thereof, or a polynucleotide having a nucleotide sequence encoding a polypeptide comprising an avian zona pellucida protein or an immunogenic fragment thereof. The avian zona pellucida protein is preferably, but need not be, substantially pure. The avian zona pellucida protein or immunogenic fragment thereof can be a naturally occurring protein, a chemically or enzymatically synthesized protein, or a recombinant protein. The avian zona pellucida protein or immunogenic fragment thereof is preferably, but need not be, glycosylated. In a glycosylated avian zona pellucida protein (i.e., an avian zona pellucida glycoprotein), the glycosylation pattern is preferably equivalent to the glycosylation pattern found on a native (i.e., naturally occurring) glycoprotein. Naturally occurring avian zona pellucida protein is preferably obtained from a chicken. Avian zona pellucida protein can be conveniently obtained from bird ovaries or from an egg cell of the bird and/or the surrounding extracellular matrix and tissue, particularly the perivitelline membrane, for example from an oocyte or unfertilized egg of a bird at any stage of development.

In a preferred embodiment of the fertility impairing vaccine, the avian zona pellucida protein used in the vaccine or encoded by the

polynucleotide used in the vaccine is a total avian zona pellucida protein. A total avian zona pellucida protein preparation includes a plurality of immunoreactive proteins, some of which have been identified in chickens as gp42 and gp97 (Y. Takeuchi et al., Eur. J. Biochem. 260:736-742 (1999)), and gp34 and gp95 (M. Wacławek et al., Biol. Reprod. 59:1230-1239 (1998)). Example I, below, identifies immunoreactive chicken proteins having molecular weights of 70 kD, 40 kD and 35 kD. The fertility impairing vaccine can, alternatively, contain fewer than all the avian zona pellucida proteins; for example it can contain the 40 kD and the 35 kD proteins but not the 70 kD protein.

Purity of the avian zona pellucida protein or glycoprotein can be evaluated analytically using a combination or series of two-dimensional polyacrylamide gel electrophoresis, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) with both silver staining and Coomassie Blue staining, and Western blot analysis, as described in the following Examples. Glycoproteins typically migrate electrophoretically in gels as broad smears rather than narrow bands, as a result of the variable levels of negative charge present in the constituent oligosaccharide chains. A total avian zona pellucida protein preparation isolated from bird eggs typically migrates as three distinct smears in the gel electrophoretic experiments, and shows the immunological reactivity in Western blot analysis using a polyclonal antibody raised in rabbits to highly purified total porcine zona pellucida protein. In a substantially pure avian zona pellucida protein preparation, no contaminating proteins having electromigration patterns different from those exhibited by the avian zona pellucida proteins are detectable in the two-dimensional gel, the SDS-PAGE gel, or Western blot analyses.

An immunogenic fragment of an avian zona pellucida protein or glycoprotein is a peptide fragment, preferably a glycosylated peptide fragment, that elicits an immune response in a subject to which it is administered. An immune response includes either or both of a cellular immune response or production of antibodies, and can include activation of the subject's B cells, T cells, helper T cells or other cells of the subject's immune system. For example,

an immune response is evidenced by a detectable anti-aZP antibody level in the subject using ELISA substantially as described in Example III.

Immunogenicity of an avian zona pellucida protein fragment can be determined, for example, by administering the adjuvanted candidate fragment to the subject, then observing of the associated immune response by analyzing anti-aZP fragment antibody titers in serum. An immunogenic peptide fragment preferably contains more than seven amino acids, more preferably at least about 10 amino acids, most preferably at least about 20 amino acids.

In a preferred embodiment of the fertility impairing vaccine, the polypeptide used in the vaccine or encoded by the polynucleotide used in the vaccine further includes at least one epitope, such as a T cell, helper T cell or B cell epitope. The epitopes can be derived from the species to which the vaccine is to be administered, from the species that was the source of the zona pellucida protein or immunogenic fragment thereof, or from any other species, including a virus, bacterium, or parasite. T cell, helper T cell or B cell epitopes or epitope mimics have been identified in zona pellucida proteins (Garza et al., J. Reprod. Immunol., February 1998, pp. 87-101). The use of immune cell epitopes derived from an immunogenic organism, such as a pathogenic parasite, is preferred. For example, the polynucleotide can encode a chimeric peptide comprising a T cell or helper T cell epitope from a parasite and a B cell epitope from a zona pellucida protein, such as a porcine or avian zona pellucida protein (Bagavant et al., Biol. Reprod., March 1997, pp. 764-770). A vaccine for use as an immunosterilant preferably contains a polypeptide that contains at least one T cell epitope (or a polynucleotide functionally encoding such a polypeptide), whereas a vaccine for use as an immunocontraceptive preferably includes a polypeptide that encodes at least one B cell epitope (or a polynucleotide functionally encoding such a polypeptide).

A polynucleotide encoding the polypeptide comprising the avian zona pellucida protein or immunogenic fragment thereof can include DNA, RNA, a modified nucleic acid, or any combination thereof. The polynucleotide can be supplied as part of a vector or as a "naked" polynucleotide. General methods for construction, production and administration of polynucleotide vaccines are known in the art, e.g. F. Vogel et al., *Clin. Microbiol. Rev.* 8:406-

410 (1995). Polynucleotides can be generated by means standard in the art, such as by recombinant techniques, or by enzymatic or chemical synthesis.

A polynucleotide used in a fertility impairing vaccine of the invention is preferably one that functionally encodes an avian zona pellucida protein. A protein is "functionally encoded" if it is capable of being expressed from the genetic construct that contains it. For example, the polynucleotide can include one or more expression control sequences, such as *cis*-acting transcription/translation regulatory sequences, including one or more of the following: a promoter, response element, an initiator sequence, an enhancer, a ribosome binding site, an RNA splice site, an intron element, a polyadenylation site, and a transcriptional terminator sequence, which are operably linked to the coding sequence and are, either alone or in combination, capable of directing expression in the target animal. An expression control sequence is "operably linked" to a coding sequence if it is positioned on the construct such that it does, or can be used to, control or regulate transcription or translation of that coding sequence. Preferred expression control sequences include strong and/or inducible *cis*-acting transcription/translation regulatory sequences such as those derived from metallothionine genes, actin genes, myosin genes, immunoglobulin genes, cytomegalovirus (CMV), SV40, Rous sarcoma virus, adenovirus, bovine papilloma virus, and the like.

The coding and expression control sequences for the avian zona pellucida protein are preferably constructed in a vector, such as a plasmid of bacterial origin, a cosmid, episome, or a viral vector, for administration to a target animal. A vector useful in the present invention can be circular or linear, single-stranded or double stranded. There are numerous plasmids known to those of ordinary skill in the art useful for the production of polynucleotide vaccine plasmids. A specific embodiment employs constructs using the plasmid pcDNA3.1 as the vector (InVitrogen Corporation, Carlsbad, CA). In addition, the vector construct can contain immunostimulatory sequences (ISS) that stimulate the animal's immune system. Other possible additions to the polynucleotide vaccine constructs include nucleotide sequences coding cytokines, such as granulocyte macrophage colony stimulating factor (GM-CSF) or interleukin-12 (IL-12). The cytokines can be used in various combinations to

fine-tune the response of the animal's immune system, including both antibody and cytotoxic T lymphocyte responses, to bring out the specific level of response needed to affect the animal's reproductive system.

Alternatively, the vector can be a viral vector, including an
5 adenovirus vector, and adenovirus associated vector, or a retroviral vector. Preferably the viral vector is a nonreplicating retroviral vector such as the Moloney murine leukemia virus (N2) backbone as described by Irwin et al. (*J. Virology* 68:5036-5044 (1994)).

10 Optionally, a fertility impairing protein vaccine of the invention further includes a polypeptide comprising a porcine zona pellucida protein or an immunogenic fragment thereof. The porcine zona pellucida protein or immunogenic fragment thereof can be a naturally occurring protein, a chemically or enzymatically synthesized protein, or a recombinant protein. The
15 porcine zona pellucida protein or immunogenic fragment thereof is preferably, but need not be, glycosylated. In a glycosylated porcine zona pellucida protein (i.e., a porcine zona pellucida glycoprotein), the glycosylation pattern is preferably equivalent to the glycosylation pattern found on a native (i.e., naturally occurring) glycoprotein. Immunogenicity of the porcine zona
20 pellucida fragment is as generally described for avian zona pellucida protein. Without intending to be bound by any particular theory or mechanism, the porcine zona pellucida protein or immunogenic fragment thereof can be included in the fertility impairing vaccine as an adjuvant to enhance the recipient's
25 immune response, or for its independent and/or synergistic effect in impairing fertility in the recipient. For example, a fertility impairing protein vaccine substantially comprising chicken zona pellucida protein, which is readily available and relatively inexpensive to isolate, can be augmented by the addition of a small amount of porcine zona pellucida protein, which is more difficult and expensive to obtain. Notwithstanding the above, any desired ratio of avian zona
30 pellucida protein to porcine zona pellucida protein can be used in this embodiment of the vaccine of the invention. The relative amounts of avian zona pellucida protein and porcine zona pellucida protein used in this embodiment of the vaccine depend on the nature of the animal being vaccinated and the immunogenic response generated in the animal by the vaccine. Preferably the

ratio of avian zona pellucida to porcine zona pellucida (aZP: pZP) used in this embodiment of the vaccine is between 100:1 and 1:100.

Similarly, a polynucleotide vaccine of the invention optionally includes, in addition to a polynucleotide encoding a avian zona pellucida protein or immunogenic fragment thereof, a polynucleotide encoding a porcine zona pellucida protein or an immunogenic fragment thereof. The porcine zona pellucida polynucleotide functionally encodes porcine zona pellucida protein and can take the form of various genetic constructs as generally described for the polynucleotide encoding avian zona pellucida protein. Polynucleotides encoding avian and porcine zona pellucida proteins can constitute part of the same vector or can be delivered to the recipient on different vectors.

The fertility impairing vaccine of the invention, whether it contains a polypeptide (e.g., conjugated or non-conjugated avian zona pellucida protein) or a polynucleotide encoding a polypeptide, optionally further includes an immunological adjuvant to enhance the immunological response of the subject to the immunogenic polypeptide or polynucleotide. Examples of adjuvants include Freund's Complete Adjuvant, Freund's Incomplete Adjuvant, Freund's mycotoxin free adjuvant, aluminum hydroxide, EQUIMUNE (a deproteinized highly purified cell wall extract derived from non-pathogenic *Mycobacteria* spp., Acemannan (a long-chain polydispersed $\beta(1,4)$ linked mannan polymer interspersed with O-acetylated groups, permulum, and an adjuvant comprising an immunostimulant such as synthetic trehalose dicorynomycolate (STDCM). The vaccine can also optionally include an oil, such as squalene oil, drakeol, or vegetable oil, which can also have an adjuvant effect (see P. Willis et al., J. Equine Vet. Sci., 14, 364-370 (1994)). It should be noted, however, that companion birds exhibit a sensitivity to oil-based adjuvants, which cause necrotic granulomas at the site of administration. An adjuvant comprising synthetic trehalose dicorynomycolate, squalene oil, and a surfactant such as lecithin is preferred for use in mammals. Lecithin typically includes phosphatidyl choline. An adjuvant comprising aluminum hydroxide is preferred for use in birds.

When an oil adjuvant is used, homogenization of the adjuvant, such as Freund's adjuvant, with the aqueous zona pellucida protein or polynucleotide

5 solution can be accomplished using any convenient means known in the art, such that the oil disperses within the aqueous solution to form an oil in water emulsion. Oil droplet sizes of about 200 nm or less are particularly preferred as they produce a more uniform and stable suspension. A particularly preferred fertility impairing vaccine comprises a predetermined amount of zona pellucida protein or polynucleotide and a pharmaceutically acceptable immunogenic level of adjuvant in an emulsion containing about 10% oil phase and about 90% aqueous phase.

10 In another embodiment of the invention, the fertility impairing vaccine, whether it contains a conjugated or a non-conjugated avian zona pellucida protein or a polynucleotide encoding said polypeptide, contains no adjuvant; essentially the fertility impairing vaccine of this embodiment is an aqueous avian zona pellucida protein or polynucleotide solution that delivers the intended amount of avian zona pellucida protein or polynucleotide to the recipient.

15 In a preferred embodiment of the protein vaccine for use in mammals, the vaccine comprises oil, preferably a biodegradable oil such as squalene oil, in an amount of about 2.5% to about 15%, preferably about 8% to about 12%. In preparing the composition it is advantageous to combine a concentrated oily adjuvant composition with an aqueous solution of the immunogen, aZP protein. Typically, the composition is prepared using an adjuvant concentrate which contains lecithin (about 5% to about 15 % wt/vol, preferably about 12% wt /vol) and STDCM (preferably about 25 mg/mL to about 50 mg/mL) in squalene oil. The term % wt/vol means grams per 100 mL of liquid. The aqueous solution containing the isolated aZP protein is typically a phosphate-buffered saline (PBS) solution, and additionally preferably contains Tween 80 (about 0.2% vol/vol to about 0.8% vol/vol, preferably about 0.4% vol/vol). See J.A. Rudbach et al., "Ribi Adjuvants: Chemistry, Biology and Utility in Vaccines for Human and Veterinary Medicine," in The Theory and Practical Application of Adjuvants, D.E.S. Stewart-Tull, Ed., John Wiley & Sons, New York, NY (1995)). Homogenization of the oily adjuvant concentrate with the aqueous aZP solution can be accomplished using any convenient means known in the art, such that the oil disperses within the aqueous solution to form

an oil in water emulsion. Oil droplet sizes of about 200 nm or less are particularly preferred as they produce a more uniform and stable suspension. A particularly preferred vaccine comprises predetermined amounts of aZP and STDCM in an emulsion containing about 10% squalene oil and about 90% aqueous phase.

The fertility impairing vaccine is administered in a manner effective to cause impaired fertility in an animal. An "animal," as that term is used herein, is an oocyte-producing organism that is capable of voluntary mobility. Preferred animals include mammals and birds. More preferably, the animal is a mammal; most preferably it is a deer, horse, elephant, rat, mouse, rabbit, ferret, cat or dog. Birds include but are not limited to free-ranging birds and domesticated birds, including food birds such as chickens, turkeys, and waterfowl, and companion birds in the order Psittaciformes, Passeriformes, Columbiformes, Falconiformes, such as budgerigars, canaries, finches, cockatiels, lovebirds, pigeons, doves and hawks.

Impairment of fertility in an animal in accordance with the invention can take the form of either immunocontraception and immunosterilization. Immunosterilization means permanent, irreversible infertility, in contrast to immunocontraception wherein infertility is temporary or transient, and reversible. Immunocontraception and immunosterilization are both dependent on the antibody titer level in the serum of the subject, but immunosterilization is typically the result of ovarian pathology caused by the immune response of the animal, as evidenced by, for example, total destruction of the zona pellucida proteins and/or influx of leukocytes into the follicles. Reducing the number of boosters leads to reduced immune response which results in immunocontraception (i.e., infertility that is temporary and reversible) instead of immunosterilization.

Optionally, the zona pellucida protein can be conjugated to an immunogenic carrier protein. A conjugated form of an avian zona pellucida protein is suitable for use in embodiments of the fertility impairing vaccine containing an avian zona pellucida protein that is homologous with respect to the intended recipient; that is, where the avian zona pellucida protein is isolated from the same species to which it is to be administered. For example, where a

fertility impairing vaccine comprising chicken zona pellucida protein is intended for administration to chickens, it may be desirable to conjugate the chicken zona pellucida protein to an immunogenic carrier to augment the immune response of the recipient. However, it is to be understood that the invention includes
5 administration of avian zona pellucida protein from any avian source to any bird, whether homologous or heterologous, and whether the avian zona pellucida protein is conjugated or unconjugated. For example, the invention includes administration of a fertility impairing vaccine comprising an unconjugated chicken zona pellucida to psittacine birds.

10 The fertility impairing vaccine is administered in a manner and an amount effective to cause the desired infertility in the animal. For example, to immunosterilize a dog or a cat using a protein vaccine of the invention, the vaccine is preferably administered in the form of a plurality of doses (typically about 1.0 mL for a dog, 0.5 mL for a cat), each dose containing avian zona
15 pellucida protein or an immunogenic fragment thereof (or a mixed vaccine containing both avian and porcine zona pellucida proteins), in an amount of about 100 μ g to about 2 mg, more preferably about 100 μ g to about 400 μ g. To treat a bird, for example, a protein vaccine is preferably administered in the form of a plurality of doses (typically about 0.25 mL), each dose containing avian
20 zona pellucida protein or an immunogenic fragment thereof (or a mixed vaccine containing both avian and porcine zona pellucida proteins), in an amount of about 10 μ g to about 2 mg, more preferably about 50 μ g to about 400 μ g.

A polynucleotide vaccine is preferably administered in one or more doses containing the plasmid, viral vector or naked polynucleotide in an amount
25 of about 5 μ g to about 100 μ g. One of skill in the art can readily determine a suitable dosage for a particular animal, depending on the nature, size and overall health of the animal, as well as the condition to be treated.

For vaccines administered to mammals, an immunostimulant such as STDCM is typically present in a per dose amount of about 50 μ g to about 5
30 mg, preferably in an amount of about 200 μ g to about 3.5 mg, more preferably in an amount of about 400 μ g to about 3.0 mg. For vaccines administered to birds, an immunostimulant such as STDCM is optionally present in a per dose amount of about 10 μ g to about 5 mg, preferably in an amount of about 50 μ g to about

3.5 mg, more preferably in an amount of about 1 mg to about 3 mg. When administered to a bird, the fertility impairing vaccine preferably contains AIOH as an adjuvant, or contains no adjuvant at all.

5 An initial injection of the vaccine is followed by one or more
booster injections at two to four week intervals, although the boosters can be
administered from about 9 days to about twelve months following the previous
vaccination. Preferably, two booster shots are administered following the initial
administration. The body's immunological response to the vaccine at this
10 dosing regimen is expected to render the ovaries permanently inactive as a result
of, for example, follicle disruption or destruction, as evidenced by
immunocytochemical analysis and histological evaluation of the ovarian tissue
of vaccinated subjects. Sterility is permanent and irreversible.
Immunosterilization of animals in accordance with the present method is not
expected to cause abnormal estrus cycles or other significant undesirable side
15 effects in the vaccinated subjects.

When the fertility impairing vaccine is administered to a dog or a
cat as described above, but with only one booster instead of two or more
boosters, the vaccine is expected to result in immunocontraception (i.e.,
temporary or transient, reversible infertility) rather than immunosterilization.
20 Fertility impairment in dogs in accordance with the present method preferably is
not expected to cause abnormal estrus cycles or other significant undesirable
side effects in the vaccinated subjects.

Although the fertility impairing vaccine is typically administered
by way of intramuscular injection, other forms of administration are also
25 contemplated, including subcutaneous or intradermal administration, oral
administration, as by food or water, topical administration, including
transdermal administration, aerosol administration, cloacal or vaginal
administration, intracoelomic administration, intranasal administration, and
transconjunctival administration, including the use of eye drops. In addition,
30 liposome-mediated, microsphere-mediated, and microencapsulation systems are
all included as delivery vehicles for the fertility impairing vaccine of the present
invention. The fertility vaccine can be formulated as a single dose vaccine and
packaged for delivery through a dart or a bullet, such that it can be administered

to an animal from a distance. A single shot time-release delivery vehicle is also contemplated, wherein the avian zona pellucida protein or immunogenic fragment thereof (or the polynucleotide encoding the avian zona pellucida or immunogenic fragment thereof) is supplied in a single dose in two or more different forms, such as a free protein and a microencapsulated protein, to allow administration of the immunogenic agent to the animal over a longer period of time.

Advantages of the invention are illustrated by the following examples. However, the particular materials and amounts thereof recited in these examples, as well as other conditions and details, are to be interpreted to apply broadly in the art and should not be construed to unduly restrict or limit the invention in any way.

EXAMPLES

Example I. Isolation of Avian Zona Pellucida Proteins

Perivitelline membranes were obtained from laid chicken eggs. Yolks were separated from whites by making a small hole in the egg and draining the albumin. The yolks were removed from the shell and the chalazae was removed and discarded. The perivitelline membranes (pvm) were either manually peeled away or punctured to drain the yolk, and the membranes were washed in sterile phosphate buffered saline solution. A tissue homogenizer (Powergam 700D) was used to homogenize the membranes. M. Wacławek et al. (Biol. Reprod., 59, 1230-1239 (1998)) reported a similar procedure for isolating perivitelline membranes from laid eggs that can also be used. Alternatively, perivitelline membranes can be isolated directly from ovarian follicles by preparing granulosa cell sheets substantially as described by A. Gilbert et al, J. Reprod. Fertil., 50, 179-181 (1977)).

Purity was demonstrated and confirmed using one-dimensional and two-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis combined with Western blot analysis, silver staining, and, at times, Coomassie

blue staining, using standard protocols. Proteins having molecular weights of 70 kD, 40 kD and 35 kD reacted with rabbit anti-pZP serum. Yolk and albumin controls did not react with the rabbit anti-pZP serum. The 70 kD protein was easily washed away from the perivitelline membrane. The 35 kD protein was approximately twice as abundant as the 40 kD protein and both had strong reactivity to the anti-pZP serum. One or both of these proteins are likely to be homologous to mammalian ZP3 (also known as ZPC), according to published reports (Y. Takeuchi et al., Eur. J. Biochem., **260**, 736-742 (1999); M. Wacławek et al., Biol. Reprod., **59**, 1230-1239 (1998)).

Example II. Preparation of Avian Zona Pellucida (aZP) Vaccine

The vaccine is prepared by homogenizing a concentrated oily adjuvant concentrate with an aqueous antigen solution containing isolated aZP protein. The oily adjuvant concentrate contains a surfactant, lecithin, and an immunostimulant, synthetic trehalose dicorynomycolate (STDCM), in squalene oil. A typical adjuvant concentrate contains about 12% wt/vol (grams/100 mL) lecithin and about 25-50 mg/mL STDCM in squalene oil. The aqueous antigen solution contains the aZP protein preparation in saline or phosphate buffered saline (PBS) and Tween 80. When prepared for use in combination with an adjuvant concentrate to yield the vaccine composition, the aqueous composition typically contains 0.4% (vol/vol) Tween 80 and an amount of aZP calculated to yield a dose of about 100 µg to about 400 µg per vaccination. Vaccine doses for dogs are about 1 mL in volume.

Homogenizing is accomplished by combining adjuvant concentrate (to a final concentration of no greater than 10% vol/vol) with aqueous aZP solution and emulsifying using a Powergam 700D homogenizer at 15,000 rpm for 6 minutes. The resulting emulsion is then homogenized with phosphate buffered saline (PBS) (containing 0.4% vol/vol Tween 80) at 20,000 for 8-12 minutes. The homogenization process results in a vaccine composition that is an oil-in-water emulsion or possibly a water-in-oil-in-water emulsion. While the inventors do not intend that the invention be bound by any particular scientific theory, it is believed that the STDCM, an amphiphilic glycolipid, partitions to

the oil/water interfaces in the emulsion, and that the antigen is attracted to and associates with the STDCM at these interfaces.

Example III. Immunosterilization of Dogs using aZP Vaccine

5

Vaccinations. Female dogs are vaccinated with 200 µg of aZP per dose in a vaccine adjuvanted with synthetic trehalose dicorynomycolate (STDCM, commercially available from RIBI Immunochem Co., Hamilton, MT) in squalene oil. The amount of STDCM per dose was about 100 µg to about 2.5 mg. A 10X adjuvant concentrate as described in Example II is available from RIBI Immunochem Co., Hamilton, MT, and vaccines are prepared as described in Example II. Boosters (containing the same amount of aZP, 200 µg) are administered at 14-day intervals. Vaccinations are delivered to dogs intra-muscularly in the longissimus muscle (loin area). Booster injections are administered on the contra-lateral side.

Antibody titers. Blood is drawn from each dog weekly, and serum antibody titers are determined using an enzyme linked immunosorbant assay (ELISA). Adjacent wells of a microwell plate are coated with 2 µg aZP, and incubated for 6 hours. The wells are then blocked with 5% bovine serum albumin (Sigma Chemical Co., St. Louis, MO) in TBST (Tris-buffered saline + 5% Tween-20) and incubated overnight. Wells are then loaded with the primary antibody (canine serum) in TBST at a 1:500 and 1:1,000 dilution and incubated for 4 hours. The wells are then washed and loaded with 50 µl of the secondary antibody (rabbit anti-dog IgG) and incubated for 2 hours. Color change is observed after the addition of *p*-nitrophenyl phosphate for 30 minutes and the reaction terminated by the addition of 3 M NaOH. The optical density is read at a 405-492 nm range on a Spectramax spectrophotometer. The dog's pre-immune serum serves as the negative control.

**Example IV. Administration of Mixed Chicken/Porcine ZP Vaccine
to Psittacines**

5 Vaccinations. Chickens are vaccinated with 200 µg of mixed zona
pellucida protein (1:1, aZP:pZP) per dose (1 mL volumes) in a vaccine
adjuvanted with Freund's complete adjuvant. The birds are vaccinated with
three injections administered at approximately two week intervals. Under
veterinary supervision, vaccinations are delivered to chickens intramuscularly in
the deep pectoral muscle. Booster injections are administered on the
10 contra-lateral side.

15 Antibody titers. Blood is drawn from each bird at the time of each of the
three injections, and about three weeks following the last injection. Serum
antibody titers (IgG) are determined using an enzyme linked immunosorbant
assay (ELISA). Adjacent wells of a microwell plate are coated with 2 µg aZP,
and incubated for 6 hours. The wells are then blocked with 5% bovine serum
albumin (Sigma Chemical Co., St. Louis, MO) in TBST (Tris-buffered saline +
5% Tween-20) and incubated overnight. Wells are then loaded with the primary
antibody (i.e., avian serum) in TBST at a 1:500 and 1:1,000 dilution and
incubated for 4 hours. The wells are then washed and loaded with 50 µl of the
20 secondary antibody (rabbit anti-chicken IgG) and incubated for 2 hours. Color
change is observed after the addition of *p*-nitrophenyl phosphate for 30 minutes
and the reaction is terminated by the addition of 3 M NaOH. The optical density
is read at a 405-492 nm range on a Spectramax spectrophotometer. The
chickens' pre-immune serum serves as the negative control.

25 Egg laying. Eggs are counted beginning on the day of the first
injection to evaluate reduction in egg production, providing direct evidence of
fertility impairment.

30 The complete disclosure of all patents, patent applications, and
publications cited herein are incorporated by reference. The foregoing detailed
description and examples have been given for clarity of understanding only. No
unnecessary limitations are to be understood therefrom. The invention is not

limited to the exact details shown and described, for variations obvious to one skilled in the art will be included within the invention defined by the claims.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221